These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 23608834)

  • 1. Concurrent involved-field radiotherapy and XELOX versus XELOX chemotherapy alone in gastric cancer patients with postoperative locoregional recurrence.
    Yuan ST; Wang FL; Liu N; Liu YH; Liu SG; Huang Y; Li YQ; Liu XB; Zhang Y; Li WH; Yu J; Zhang JD
    Am J Clin Oncol; 2015 Apr; 38(2):130-4. PubMed ID: 23608834
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Concurrent involved-field radiotherapy and XELOX in gastric cancer patients with postoperative oligometastatic recurrence.
    Xu C; Xie J; Liang N; Wang J; Qiao L; Luo H; Zhang JX; Zhang J
    J Cancer Res Ther; 2014 Dec; 10 Suppl():267-71. PubMed ID: 25693933
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intensity-modulated radiation therapy with concurrent chemotherapy as preoperative treatment for localized gastric adenocarcinoma.
    Chakravarty T; Crane CH; Ajani JA; Mansfield PF; Briere TM; Beddar AS; Mok H; Reed VK; Krishnan S; Delclos ME; Das P
    Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):581-6. PubMed ID: 22137021
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Docetaxel, capecitabine and concurrent radiotherapy for gastric cancer patients with postoperative locoregional recurrence.
    Xie J; Liang N; Qiao L; Su L; Li K; Luo H; Zhang J; Zhang J
    Tumori; 2015; 101(4):433-9. PubMed ID: 25983095
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant IMRT/XELOX radiochemotherapy improves long-term overall- and disease-free survival in advanced gastric cancer.
    Boda-Heggemann J; Weiss C; Schneider V; Hofheinz RD; Haneder S; Michaely H; Wertz H; Ronellenfitsch U; Hochhaus A; Wenz F; Lohr F
    Strahlenther Onkol; 2013 May; 189(5):417-23. PubMed ID: 23558673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The prognostic significance of an R1 resection in gastric cancer patients treated with adjuvant chemoradiotherapy.
    Stiekema J; Trip AK; Jansen EP; Boot H; Cats A; Ponz OB; Verheij M; van Sandick JW
    Ann Surg Oncol; 2014 Apr; 21(4):1107-14. PubMed ID: 24306660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of preoperative chemotherapy regimens in patients with initially unresectable locally advanced gastric adenocarcinoma: capecitabine and oxaliplatin (XELOX) or with epirubicin (EOX).
    Wang Y; Zhuang RY; Yu YY; Yu S; Hou J; Ji Y; Sun YH; Shen KT; Shen ZB; Liu FL; Zhao NQ; Liu TS
    Oncotarget; 2016 Nov; 7(46):76298-76307. PubMed ID: 27602586
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of intensity modulated radiotherapy combined with s-1-based chemotherapy in locally advanced gastric cancer patients.
    Hu JB; Sun XN; Gu BX; Wang Q; Hu WX
    Oncol Res Treat; 2014; 37(1-2):11-6. PubMed ID: 24613903
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined adjuvant radiochemotherapy with IMRT/XELOX improves outcome with low renal toxicity in gastric cancer.
    Boda-Heggemann J; Hofheinz RD; Weiss C; Mennemeyer P; Mai SK; Hermes P; Wertz H; Post S; Massner B; Hieber U; Hochhaus A; Wenz F; Lohr F
    Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):1187-95. PubMed ID: 19409725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoadjuvant chemoradiotherapy plus postoperative adjuvant XELOX chemotherapy versus postoperative adjuvant chemotherapy with XELOX regimen for local advanced gastric cancer-A randomized, controlled study.
    Wang F; Qu A; Sun Y; Zhang J; Wei B; Cui Y; Liu X; Tian W; Li Y
    Br J Radiol; 2021 Aug; 94(1124):20201088. PubMed ID: 34260297
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Postoperative chemotherapy followed by conformal concomitant chemoradiotherapy in high-risk gastric cancer.
    Quero L; Bouchbika Z; Kouto H; Baruch-Hennequin V; Gornet JM; Munoz N; Cojean-Zelek I; Houdart R; Panis Y; Valleur P; Aparicio T; Maylin C; Hennequin C
    Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):574-80. PubMed ID: 22099038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of the extent of surgery and postoperative chemoradiotherapy on recurrence patterns in gastric cancer.
    Dikken JL; Jansen EP; Cats A; Bakker B; Hartgrink HH; Kranenbarg EM; Boot H; Putter H; Peeters KC; van de Velde CJ; Verheij M
    J Clin Oncol; 2010 May; 28(14):2430-6. PubMed ID: 20368551
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [A pilot study of chemotherapy combined with intraperitoneal perfusion of cytokine-induced killer cells for advanced gastric cancer patients with ascites].
    Wang ZM; Zhuang RY; Chen Y; Feng Y; Li Q; Liu TS
    Zhonghua Wei Chang Wai Ke Za Zhi; 2013 Jan; 16(1):28-31. PubMed ID: 23355235
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy after preoperative capecitabine and oxaliplatin (XELOX) versus docetaxel, oxaliplatin and S1 (DOS) in patients with locally advanced gastric adenocarcinoma: a propensity score matching analysis.
    Wang Y; Cheng X; Cui YH; Hou J; Ji Y; Sun YH; Shen ZB; Liu FL; Liu TS
    BMC Cancer; 2018 Jun; 18(1):702. PubMed ID: 29954358
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oxaliplatin and capecitabine-based chemoradiotherapy for gastric cancer--an extended phase I MARGIT and AIO trial.
    Hofheinz RD; Wenz F; Lukan N; Mai S; Kripp M; Staiger W; Schwarzbach M; Willeke F; Möhler M; Post S; Hochhaus A
    Int J Radiat Oncol Biol Phys; 2009 Jan; 73(1):142-7. PubMed ID: 18539404
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Postoperative intraperitoneal 5-fluoro-2'-deoxyuridine added to chemoradiation in patients curatively resected (R0) for locally advanced gastric and gastroesophageal junction adenocarcinoma.
    Cohen DJ; Newman E; Iqbal S; Chang RY; Potmesil M; Ryan T; Donahue B; Chandra A; Liu M; Utate M; Hiotis S; Pachter LH; Hochster H; Muggia F
    Ann Surg Oncol; 2012 Feb; 19(2):478-85. PubMed ID: 21769462
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant capecitabine plus oxaliplatin after D2 gastrectomy in Japanese patients with gastric cancer: a phase II study.
    Fuse N; Bando H; Chin K; Ito S; Yoshikawa T; Tsuburaya A; Terashima M; Kawashima Y; Fukunaga T; Gotoh M; Emi Y; Yoshida K; Oki E; Takahashi S; Kuriki H; Sato K; Sasako M
    Gastric Cancer; 2017 Mar; 20(2):332-340. PubMed ID: 26956689
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of intensity-modulated radiotherapy and 3-dimensional conformal radiotherapy as adjuvant therapy for gastric cancer.
    Minn AY; Hsu A; La T; Kunz P; Fisher GA; Ford JM; Norton JA; Visser B; Goodman KA; Koong AC; Chang DT
    Cancer; 2010 Aug; 116(16):3943-52. PubMed ID: 20564136
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of preoperative radiochemotherapy in patients with locally advanced pancreatic carcinoma.
    Lind PA; Isaksson B; Almström M; Johnsson A; Albiin N; Byström P; Permert J
    Acta Oncol; 2008; 47(3):413-20. PubMed ID: 17882555
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of external-beam radiation therapy on outcomes among patients with resected gastric cancer: a multi-institutional analysis.
    Ejaz A; Spolverato G; Kim Y; Squires MH; Poultsides G; Fields R; Bloomston M; Weber SM; Votanopoulos K; Worhunsky DJ; Swords D; Jin LX; Schmidt C; Acher AW; Saunders N; Cho CS; Herman JM; Maithel SK; Pawlik TM
    Ann Surg Oncol; 2014 Oct; 21(11):3412-21. PubMed ID: 24845728
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.